Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
codrug 1
- Development stage
- Preclinical
- Lead developer
- Università degli Studi Gabriele d'Annunzio Chieti e Pescara
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Codrug 1** is an experimental, lipophilic small-molecule mutual prodrug created at the University \"G. d'Annunzio\" of Chieti-Pescara by covalently linking **(R)-alpha-lipoic acid** and **ibuprofen** through a diamide linkage. It was designed to improve brain delivery of the anti-inflammatory and antioxidant parent drugs in neurodegenerative disease. In rat beta-amyloid 1-40 infusion models of Alzheimer's disease, codrug 1 showed slow conversion to ibuprofen and (R)-alpha-lipoic acid, antioxidant activity, and greater protection than ibuprofen against amyloid-associated cognitive, behavioral, biochemical, and morphological abnormalities. It is a preclinical research compound, has no assigned INN or marketed trade name, and is not an approved medicine.
- Other names
- codrug 1codrug1codrug-1compound 1compound1compound-1ibuprofen and lipoic acid diamide
02
Targets
NOS2 (Nitric Oxide Synthase 2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on codrug 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on codrug 1.